Professor Julie Fox qualified from the University of Manchester and trained in Genitourinary Medicine at Imperial College London. Julie is a Professor in HIV and Sexual Health in the School of Immunology & Microbial Sciences at King's and in addition leads the HIV clinical trials unit at Guys and St Thomas’ NHS Trust. She is Chief Investigator on National and International multi-centre infectious diseases clinical trials, collaborating with NHS/academic partners across the UK, Europe and Sub-Saharan Africa.

Her research focuses on HIV prevention (vaccine and pre-exposure prophylaxis), HIV cure, acute HIV and optimising HIV treatments. She collaborates widely and is a keen proponent of multidisciplinary research. Julie is co-founder of the UK HIV cure group: Collaborative HIV Eradication of Reservoirs: UK BRC (CHERUB) which has led internationally renowned HIV cure trials using novel therapies including broadly neutralising antibodies (RIO study), HADC inhibitors (RIVER study) and immune modulators (STRIVE study), For HIV prevention. She leads the Africa based MOBILE MEN consortium evaluating long and short acting Pre-exposure prophylaxis in men who travel for work in Uganda and South Africa. She also led the European/African combined HIV adolescent prevention group, CHAPS exploring HIV prevention in young adults in South Africa, Uganda and Zimbabwe. Furthermore, she was trial physician of the international HIV vaccine and PrEP study, PREPVACC which took place in Mozambique, South Africa, Tanzania and Uganda. In the UK, she led HOME PEP which is cited globally as pivotal research to support self-start HIV post-exposure prophylaxis.

During the COVID pandemic, Julie carried out SARS-CoV-2 research. She co-led the HIV group of the Oxford COV002 vaccine trial which showed that no vaccine dose adjustment was needed for SAR-CoV-2 vaccination in people living with HIV. In addition, she led two multidisciplinary research networks across UK, Uganda and South Africa evaluating SARS-CoV-2 antibody evolution, developing a SARS-CoV-2 ex vivo challenge model and carrying out public engagement in rural communities (COVAB and COVAB-B).

She is on guidelines committees in the UK for HIV treatment, HIV pre-exposure prophylaxis and HIV post exposure prophylaxis. Internationally, she is on the World Health Organization committees for HIV pre-exposure prophylaxis, HIV post exposure prophylaxis and HIV testing.